213 related articles for article (PubMed ID: 21120161)
1. Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia.
Kim YK; Kim HN; Lee SR; Ahn JS; Yang DH; Lee JJ; Lee IK; Shin MG; Kim HJ
Korean J Hematol; 2010 Mar; 45(1):36-45. PubMed ID: 21120161
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
3. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations.
Yoon JH; Kim HJ; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Genes Chromosomes Cancer; 2015 Aug; 54(8):489-499. PubMed ID: 26054017
[TBL] [Abstract][Full Text] [Related]
4. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
5. The incidence and prognostic effect of Fms-like tyrosine kinase 3 gene internal tandem and nucleolar phosphoprotein 1 genes in acute myeloid leukaemia: A PRISMA-compliant systematic review and meta-analysis.
Liu H; Zhang X; Li M; Zhou W; Jiang G; Yin W; Song C
Medicine (Baltimore); 2020 Dec; 99(51):e23707. PubMed ID: 33371116
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy.
Pratcorona M; Brunet S; Nomdedéu J; Ribera JM; Tormo M; Duarte R; Escoda L; Guàrdia R; Queipo de Llano MP; Salamero O; Bargay J; Pedro C; Martí JM; Torrebadell M; Díaz-Beyá M; Camós M; Colomer D; Hoyos M; Sierra J; Esteve J;
Blood; 2013 Apr; 121(14):2734-8. PubMed ID: 23377436
[TBL] [Abstract][Full Text] [Related]
7. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
8. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.
Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
[TBL] [Abstract][Full Text] [Related]
9. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.
Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics.
How J; Sykes J; Minden MD; Gupta V; Yee KW; Schimmer AD; Schuh AC; Kamel-Reid S; Brandwein JM
Blood Cancer J; 2013 May; 3(5):e116. PubMed ID: 23708641
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
[TBL] [Abstract][Full Text] [Related]
14. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
[TBL] [Abstract][Full Text] [Related]
15. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H; Wei AH; Roboz GJ; Montesinos P; Thol FR; Ravandi F; Dombret H; Porkka K; Sandhu I; Skikne B; See WL; Ugidos M; Risueño A; Chan ET; Thakurta A; Beach CL; Lopes de Menezes D
Blood; 2022 Oct; 140(15):1674-1685. PubMed ID: 35960871
[TBL] [Abstract][Full Text] [Related]
17. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
18. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
Haferlach T; Bacher U; Alpermann T; Haferlach C; Kern W; Schnittger S
Leuk Res; 2012 Jan; 36(1):51-8. PubMed ID: 21621842
[TBL] [Abstract][Full Text] [Related]
19. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
Miyashita N; Onozawa M; Yoshida S; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Fujisawa S; Mori A; Ota S; Kakinoki Y; Tsutsumi Y; Yamamoto S; Miyagishima T; Nagashima T; Ibata M; Wakasa K; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Kondo T; Teshima T
Int J Hematol; 2023 Jul; 118(1):36-46. PubMed ID: 36853451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
